Tiger Brokers

Aclaris Therapeutics Phase 2a week 12 EASI improvement climbs 77% on ATI-2138 10 mg BID; BSA improvement grows 70%

Reuters
Mar 27
<a href="https://laohu8.com/S/ACRS">Aclaris Therapeutics</a> Phase 2a week 12 EASI improvement climbs 77% on ATI-2138 10 mg BID; BSA improvement grows 70%
  • Aclaris reported additional Phase 2a results that were presented in an electronic poster at the 2026 American Academy of Dermatology Annual Meeting for ATI-2138, an investigational oral covalent inhibitor of ITK and JAK3, in moderate-to-severe atopic dermatitis.
  • At week 12, the 10 mg BID dose cohort showed a 77% improvement in EASI and a 70% improvement in affected body surface area.
  • Week 12 outcomes also included a 50% improvement in peak pruritus numerical rating scale and a 65% improvement in Dermatology Life Quality Index.
  • The company said near-complete ITK target occupancy was observed across the dosing interval and tape-strip analyses indicated modulation of multiple immune pathway markers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603271010PRIMZONEFULLFEED9679752) on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10